Future research should prioritize three areas: (1) defining FKBP51’s temporal role throughout AD progression; (2) validating its biomarker potential through longitudinal clinical studies; and (3) elucidating the molecular crosstalk between FKBP51-mediated signaling and established AD therapeutic targets. This evidence concerns the gene FKBP4 and Alzheimer disease.